Fetal and Neonatal Alloimmune Thrombocytopenia

Hematology
1
Pipeline Programs
1
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Rallybio
RallybioNEW HAVEN, CT
2 programs
1
Anti-Phase 21 trial
Clinical data collectionN/A1 trial
Active Trials
NCT05345561Completed14,390Est. Oct 2025
NCT06435845Terminated1Est. Oct 2025

Trial Timeline

Clinical trial activity over time

2022
2023
2024
2025
2026
RallybioAnti-
RallybioClinical data collection

Clinical Trials (2)

Total enrollment: 14,391 patients across 2 trials

Phase 2 Study on the Pharmacokinetics and Safety of RLYB212 in Pregnant Women at Higher Risk for HPA-1a Alloimmunization

Start: Nov 2024Est. completion: Oct 20251 patients
Phase 2Terminated
NCT05345561RallybioClinical data collection

Study to Assess the Occurrence of HPA-1a Alloimmunization in Women With Higher Risk for Fetal and Neonatal Alloimmune Thrombocytopenia

Start: Mar 2022Est. completion: Oct 202514,390 patients
N/ACompleted

Related Jobs in Hematology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space